CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Join us for a LIVE, interactive broadcast on NSCLC Friday 10/5
<< View More Conferences
2018 Miami Breast Cancer Conference
Oncology Conference Multimedia
View more videos >>
Dr. Borgen on the Evolution of Breast Cancer Treatment
Dr. Hurvitz on Novel Emerging Agents in HER2+ Breast Cancer
Dr. Robson on Exploratory Analysis From OlympiAD in Breast Cancer
Oncology Conference Articles
Managing Cardiac AEs in HER2-Positive Breast Cancer
Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.
Preventing Clinical Lymphedema With Bioimpedance Spectroscopy
Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.
Hospitalists and Nonphysician Providers Can Step Into the Breach
Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.
Looking for a Therapeutic Edge Among CDK Inhibitors
Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.
Testing the Power of Neoadjuvant Systemic Therapy in Breast Cancer
Neoadjuvant therapy can eliminate both invasive and in situ carcinoma in up to 50% of patients, particularly when their subtypes are triple-negative disease or HER2-positive cancers.
Abemaciclib Data Reviewed as New Breast Cancer Indications Added
Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.
Neoadjuvant Endocrine Therapy Ideal for Some Breast Cancer Patients
Endocrine therapy can achieve tumor reduction for patients with ER-positive breast cancer, possibly avoiding the need for chemotherapy or even surgery in some patients; however, deciding how long to continue this therapy can be tricky.
AJCC Staging Manual Gives Boost to Precision Medicine
The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer is a quantum leap toward precision oncology, as it codifies advanced knowledge of the role of biologic factors in cancer, and oncologists should now be using it.
PARP Inhibitors Arrive for BRCA+ Breast Cancer
The PARP inhibitors have finally become available for patients with
-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.
Dual Targeting Advances in HER2+/HR+ Breast Cancer
The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.
Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs
Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.
Frontline Palbociclib Effective Regardless of Prior Treatment in Breast Cancer Subgroups
Palbociclib (Ibrance) demonstrated significant efficacy in combination with letrozole (Femara) in the frontline setting of estrogen receptor-positive, HER2-negative, postmenopausal metastatic breast cancer.
Ribociclib Active Across Premenopausal Breast Cancer Subgroups
The progression-free survival benefit for ribociclib in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer was sustained across patient subgroups, according to findings from the phase III MONALEESA-7 trial.
Olaparib Breast Cancer Efficacy Highlighted in Added Analyses
Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline
Priority Review in NSCLC, Label Update in CLL, Delayed FDA Decision in Lung Cancer, and More
CLL Paradigm Continues to Be Refined
CAR T-Cell Therapy Brings Hope to Relapsed/Refractory Myeloma
Expert Addresses Advances and Challenges in Myeloma
Diagnosis of ITP Remains a Challenge for Clinicians
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.